Dr. Chlebowski on How Weight Loss Improves TNBC Survival

Video

As few as five pounds of weight loss can make a significant difference for patients with triple-negative breast cancer, says Rowan Chlebowski, MD, PhD, a medical oncologist at the Los Angeles Biomedical Research Institute at the Harbor-UCLA Medical Center.

As few as five pounds of weight loss can make a significant difference for patients with triple-negative breast cancer, says Rowan Chlebowski, MD, PhD, a medical oncologist at the Los Angeles Biomedical Research Institute at the Harbor-UCLA Medical Center.

Among patients following a program to reduce their dietary fat intake, those with estrogen receptor (ER)-negative breast cancer had a reduction of death of 36%, while ER- and progesterone receptor (PR)-negative patients had a 54% reduction of death compared to the control group.

Losing even a small amount of weight can impact factors that drive tumor growth like glucose metabolism, inflammatory factors, and diabetes, says Chlebowski.

More research is needed to validate these findings from a scientific standpoint, but because five pounds of weight loss is such a simple change, Chlebowski suggests breast cancer patients put it into practice now.

<<<

View more from the 2014 San Antonio Breast Cancer Symposium

Related Videos
Video 4 - "The Evolving Treatment Landscape with CDK4/6 Inhibitors in Early HR+/HER2- Breast Cancer"
Margaret E. Gatti-Mays, MD, MPH, FACP, of The Ohio State University Comprehensive Cancer Center
Ko Un “Clara” Park, MD
Erin Frances Cobain, MD
Video 3 - "5-Year Data from the MonarchE Trial Investigating Abemaciclib in HR+, HER2- High-Risk, Early Breast Cancer"
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Eric S. Christenson, MD
Samer A. Srour, MB ChB, MS
Rebecca L. Porter, MD, PhD
Deborah J. Wong, MD, PhD